<code id='E383364D47'></code><style id='E383364D47'></style>
    • <acronym id='E383364D47'></acronym>
      <center id='E383364D47'><center id='E383364D47'><tfoot id='E383364D47'></tfoot></center><abbr id='E383364D47'><dir id='E383364D47'><tfoot id='E383364D47'></tfoot><noframes id='E383364D47'>

    • <optgroup id='E383364D47'><strike id='E383364D47'><sup id='E383364D47'></sup></strike><code id='E383364D47'></code></optgroup>
        1. <b id='E383364D47'><label id='E383364D47'><select id='E383364D47'><dt id='E383364D47'><span id='E383364D47'></span></dt></select></label></b><u id='E383364D47'></u>
          <i id='E383364D47'><strike id='E383364D47'><tt id='E383364D47'><pre id='E383364D47'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:Wikipedia    Page View:816
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In